We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

La Jolla Pharmaceuticals Co (LJPC) Common Stock USD0.0001

Sell:$3.80 Buy:$3.91 Change: $0.01 (0.26%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
Sell:$3.80
Buy:$3.91
Change: $0.01 (0.26%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
Sell:$3.80
Buy:$3.91
Change: $0.01 (0.26%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

La Jolla Pharmaceutical Company is engaged in development and commercialization of therapies for patients suffering from life-threatening diseases. Its product pipeline include GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA (angiotensin II) injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shock. Its XERAVA (eravacycline) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. The Company's early-stage clinical development product candidate include TP-6076, TP-271, and TP-2846. Its TP-6076 is a IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia.

Contact details

Address:
201 JONES ROAD, SUITE 400
WALTHAM
02451
United States
Telephone:
+1 (617) 7153600
Website:
https://www.lajollapharmaceutical.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
LJPC
ISIN:
US5034596040
Market cap:
$107.07 million
Shares in issue:
27.52 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Kevin Tang
    Chairman of the Board
  • Larry Edwards
    President, Chief Executive Officer, Director
  • Michael Hearne
    Chief Financial Officer
  • Tony Hodges
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.